Clinical Trials Browser

OTHER × Gemtuzumab × Clear all

NCT05955261 2026-04-13

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Phase 2 Suspended

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2 Recruiting

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

NCT05558124 2026-02-27

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03672539 2026-02-20

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04915612 2026-02-20

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03737955 2026-01-28

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT03568994 2026-01-27

ATACC AML

Phase EARLY_PHASE1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05183035 2026-01-13

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01409161 2025-12-17

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT06448013 2025-12-15

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03589729 2025-11-20

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Phase 2 Recruiting

MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT03900949 2025-10-28

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04385290 2025-09-08

MOSAIC

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05716009 2025-05-06

GO-TAG

Phase 1 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04070768 2025-05-04

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

Phase 1 Completed

18 enrolled 15 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04050280 2025-05-01

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

Phase 2 Recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05662904 2025-03-14

GALAXY33

Phase 1 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03839446 2025-02-20

Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

Phase 2 Completed

16 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05599360 2024-12-02

Vyxeos for Induction of Low- or Intermediate-risk.

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05904106 2024-12-02

VINCENT

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04168502 2024-11-08

Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04207190 2024-11-01

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04793919 2024-04-15

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT03374332 2024-02-08

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Phase 2 Active not recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Disease Progression

NCT02473146 2024-02-02

ALFA1401

Phase 2/3 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03904251 2023-11-18

CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT02117297 2023-10-26

SCT Plus Immune Therapy in Average Risk AML/MDS

Phase 2 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02221310 2023-10-26

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

Phase 2 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03390296 2023-09-05

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Completed

50 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03531918 2023-08-30

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

Phase 1/2 Completed

66 enrolled 18 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04173585 2023-03-27

TEAM

Phase 2 Completed

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03878927 2023-03-10

CPX GO

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00893399 2023-02-27

Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation

Phase 3 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03848754 2022-06-30

Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04326439 2022-06-15

AflacLL1901 (CHOA-AML)

Phase 2 Terminated

8 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02724163 2021-10-08

Myechild01

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT01020539 2021-08-06

AML/MDS/JMML

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Juvenile

NCT02272478 2020-01-23

AML18

Phase 2/3 Unknown

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00413166 2019-05-07

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

Phase 2 Completed

78 enrolled 10 charts

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT00766116 2019-02-18

Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

Phase 1/2 Completed

50 enrolled 6 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00038805 2018-10-31

Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)

Phase 2/3 Terminated

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01548911 2018-07-02

Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia

Phase 2 Withdrawn

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

NCT01869803 2018-03-02

Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia

Approved for marketing

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

NCT03287128 2018-01-24

MYLOR

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00673153 2017-06-01

Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2 Terminated

31 enrolled 11 charts

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00860639 2017-01-27

LAM2006IR

Phase 3 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00121303 2016-09-20

Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Phase 3 Completed

Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00006265 2016-07-14

Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT00476541 2016-05-13

NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia

Phase 3 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00660036 2016-01-15

Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

Phase 1 Terminated

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute